DavidRosmarinMD
Dermatology • Indianapolis, INInstructor in Dermatology, Brigham and Women's Hospital
Dr. Rosmarin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
550 University Blvd
Ste 3240
Indianapolis, IN 46202Phone+1 317-948-8657Fax+1 317-944-7051
Education & Training
Boston University Medical CenterResidency, Dermatology, 2006 - 2009
New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 2005 - 2006
New York University School of MedicineClass of 2005
Certifications & Licensure
IN State Medical License 2022 - 2025
MA State Medical License 2008 - 2023
NY State Medical License 2013 - 2016
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Clinical Trials
- A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis Start of enrollment: 2016 Apr 01
- Topical Ruxolitinib for the Treatment of Vitiligo Start of enrollment: 2016 Jan 01
- Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa Start of enrollment: 2016 Jul 11
- Join now to see all
Publications & Presentations
PubMed
- The association between obesity and efficacy of psoriasis therapies: An expert consensus panel.Joshua Burshtein, April Armstrong, May Chow, Lauren DeBusk, Brad Glick
Journal of the American Academy of Dermatology. 2025-04-01 - Repigmentation by body region in patients with vitiligo treated with ruxolitinib cream over 52 weeks.Thierry Passeron, John E Harris, Amit G Pandya, Julien Seneschal, Pearl Grimes
Journal of the European Academy of Dermatology and Venereology. 2025-03-01 - Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.Jacob P Thyssen, David Rosmarin, Antonio Costanzo, Richard Warren, Chia-Yu Chu
Dermatology. 2025-01-01
Press Mentions
Maintenance of Low Eczema Activity Seen After About 80 Days off TapinarofMarch 14th, 2025- Adolescents with Vitiligo Achieve Higher Repigmentation Rates with Topical Ruxolitinib Than AdultsJuly 16th, 2024
- Seeing Red with DupilumabMarch 1st, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
